Clinical trials involving patients with VHL disease and unresectable HBs have historically explored the use of tyrosine kinase inhibitors (targeting genes from the VEGFR, PDGFR, and EGFR families, which are regulated by the HIF pathway), such as semaxanib, vatalanib, sunitinib, and pazopanib, as well as monoclonal anti-VEGF antibodies (bevacizumab). Here, PDGFRB is linked to von Hippel-Lindau disease.